Effect of Anabolic Testosterone on CA 19-9 Levels

Understanding CA 19-9 as a Tumor Marker

CA 19-9 is a tumor-associated antigen originally defined by a monoclonal antibody produced from murine spleen cells immunized with human colorectal cancer cell lines, and it exists as an epitope of sialylated Lewis A blood group antigen 1
Approximately 5-10% of the population is genotypically Lewis ab-negative and cannot produce CA 19-9, making testing ineffective in these individuals 1, 2

CA 19-9 serves as a nonspecific marker that can be elevated in biliary tract cancer and other gastrointestinal malignancies, and elevated levels are associated with poorer prognosis in cancer patients 3
CA 19-9 is not recommended as a screening test for pancreatic cancer due to inadequate specificity and sensitivity, and it can be elevated in many non-malignant conditions, including inflammatory conditions of the hepatobiliary system and biliary obstruction 1, 4
Elevated CA 19-9 levels can be useful for assessing treatment response in cancer patients 3

Acute cholestatic syndrome is a hepatotoxic effect associated with anabolic steroid use 2
Hepatic tumors are a potential hepatotoxic effect of anabolic steroid use 4

CA 19-9 can be elevated in hepatobiliary conditions and biliary obstruction, which can be caused by anabolic steroid-induced liver injury 1, 3

Re-evaluation of CA 19-9 levels after discontinuation of anabolic steroids can help determine if levels normalize 4
If CA 19-9 remains elevated after steroid discontinuation, further investigation for other causes is warranted, according to the American Society of Clinical Oncology 1, 3